ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETFの空売り状況は、投資家がETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETFの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF (BATS:MSTU), 空売り情報

T-Rex 2X Long MSTR Daily Target ETF

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF

Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>) has been in a prolonged downtrend, leading traders to question whether market makers or retail investors are behind the <a href="https://www.benzinga.com/money/floki-price-prediction">bearish price action</a>. &nbsp;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>)</td>
<td>&nbsp;$0.00009245</td>
<td>$888.9 million</td>
<td>-5.3%&nbsp;</td>
<td>-6.7%&nbsp;</td>
</tr>
<tr>
<td>Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>)</td>
<td>&nbsp;$0.00001754</td>
<td>$1.35 billion</td>
<td>-4.5%&nbsp;</td>
<td>-5.5%&nbsp;</td>
</tr>
<tr>
<td>SPX6900 (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SPX</a>)</td>
<td>&nbsp;$0.7209</td>
<td>$671.2 million</td>
<td>-7.6%&nbsp;</td>
<td>-7.8%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Master Kenobi noted that FLOKI has erased all gains from the past year, with market makers aggressively extracting liquidity. 
Unlike Dogecoin, FLOKI never saw a true bull market, launching at the tail end of the 2021 cycle. 
It crashed 98%, rebounded to an all-time high in 2024, and has since been in a 240-day decline.
An estimated 90% of FLOKI's supply is controlled by market makers, suggesting that a large pump could happen if retail FOMO kicks in. 
Binance's connection to FLOKI remains unclear but could be strategic—with FLOKI locking up significant BNB liquidity, Binance may see it as a way to boost BNB's ecosystem.
At its valuation, a 10X-20X rally could be possible in a bull market, especially if BNB hits four-digit levels. 
Still, the trader wonders how much of the price action is organic.
Statistics: IntoTheBlock data shows Floki's large transaction volume expanded 135.8% in the past 24 hours while daily active addresses were down by 8.9%.
Transactions greater than $100,000 remained relatively flat at 9.
Coinglass data shows open interest down by 8.7% in a single day to $14.9 million. In December 2024, open interest had peaked to $48.7 million.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43636904/anthony-scaramucci-warns-meme-coins-create-market-contagion-fuel-bitcoin-skepticism">Anthony Scaramucci Warns Meme Coins Create Market Contagion, Fuel Bitcoin Skepticism</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BONK

$FLOKI

$SPX

Floki Down 38% In A Month: What Is Going On?

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and raises the price target from $11.5 to $13.5.

Price Target

Analyst Ratings

TDOC

B of A Securities Maintains Neutral on Teladoc Health, Raises Price Target to $13.5

NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) reported quarterly earnings of $0.06 per share. This is a 142.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported $3.27 million in sales this quarter. This is a 234.89 percent increase over sales of $977.65 thousand the same period last year.

Earnings

NMTC

NeuroOne Medical Tech Q1 EPS $0.06 Up From $(0.14) YoY, Sales $3.27M Up From $977.65K YoY

Canaccord Genuity analyst Whitney Ijem upgrades Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Sell to Hold and raises the price target from $408 to $424.

Upgrades

VRTX

Canaccord Genuity Upgrades Vertex Pharmaceuticals to Hold, Raises Price Target to $424

On Wednesday, CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) reported fourth-quarter sales of $97.71 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $97.19 billion</a>.
Total revenues increased 4.2%, driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43651952/cvs-health-corporation-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">Health Services segment</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43636822/cvs-health-stock-is-relatively-cheap-analyst-highlights-cost-trend-pressure-ahead-of-q4-earnings" rel="noreferrer noopener">CVS Health Stock Is Relatively Cheap, Analyst Highlights Cost Trend Pressure Ahead Of Q4 Earnings</a>
Adjusted EPS of $1.19 decreased from $2.12 in the prior year, beating the consensus of $0.93, primarily due to a decline in the Health Care Benefits segment's operating results, which reflect continued utilization pressure and the unfavorable impact of the Company's Medicare Advantage star ratings for the 2024 payment year.
Adjusted operating income decreased 35.5% to $2.73 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43010888/ftc-says-unitedhealth-cvs-cigna-make-billions-via-pbms-on-specialty-drugs" rel="noreferrer noopener">FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs</a>
Revenues in the Health Care Benefits segment increased 23.3% to $32.96 billion, primarily driven by growth in the Medicare and individual exchange product lines.
The Medical benefit ratio increased from 88.5% to 94.8% compared to the prior year, driven by increased utilization, the unfavorable impact of the previously disclosed decline in the company's Medicare Advantage star ratings for the 2024 payment year, and the impact of higher acuity in Medicaid.
Medical membership as of December 31, 2024, of 27.1 million, increased by 1.4 million members compared with December 31, 2023, reflecting increases in the Medicare and individual exchange product lines.
Health Services segment (offering pharmacy benefit management) sales decreased 4.3% to $47.02 billion, primarily driven by the previously announced loss of a large client and continued pharmacy client price improvements. These decreases were partially offset by the pharmacy drug mix, increased contributions from the company's healthcare delivery assets, and growth in specialty pharmacy.
Pharmacy &amp; Consumer Wellness segment sales increased 7.5% to $33.51 billion, primarily driven by pharmacy drug mix and increased prescription volume.
Prescriptions filled increased by 3.3%, and Same-store prescription volume increased by 5.9% in the quarter.
Guidance: CVS Health forecasts fiscal year 2025 adjusted EPS of $5.75-$6.00 versus consensus of $5.96.
The company expects GAAP EPS of $4.58 to $4.83, with cash flow from operations guidance of approximately $6.5 billion.
In the last 12 months, CVS stock has fallen by 29%. The stock has jumped today on positive Q4 report.
Price Action:&nbsp;CVS stock is up 9.89% at $60.44 during the premarket session on last check Wednesday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43637593/astera-labs-to-outpace-its-peers-in-revenue-growth-in-2025-analyst-says" target="_blank" rel="noreferrer noopener">Astera Labs To Outpace Its Peers In Revenue Growth In 2025, Analyst Says</a></li>
</ul>
Photo: Around the World Photos via Shutterstock

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

CVS Health Q4 Earnings: Revenue And EPS Beat, Same-store Prescription Volume Up 5.9%, Upbeat FY25 Outlook And More

B of A Securities analyst Nat Schindler maintains Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) with a Underperform and raises the price target from $33 to $39.

UPST

B of A Securities Maintains Underperform on Upstart Hldgs, Raises Price Target to $39

Canaccord Genuity analyst Austin Moeller maintains Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and lowers the price target from $14 to $13.

ACHR

Canaccord Genuity Maintains Buy on Archer Aviation, Lowers Price Target to $13

Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) will release its second-quarter financial results after the <a href="https://www.benzinga.com/quote/CSCO/earnings">closing bell, on Wednesday, Feb. 12, 2025.</a>
Analysts expect the California-based company to report quarterly earnings at 91 cents per share, up from 87 cents per share in the year-ago period. Cisco projects quarterly revenue of $13.87 billion, compared to $12.79 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 10, the company introduced an AI solution in collaboration with Mistral AI, signaling a major advancement in its Customer Experience (CX) initiatives.
With the recent buzz around Cisco, some investors may be eyeing potential gains from the company's dividends too. As of now, Cisco offers an annual dividend yield of 2.56%, which is a quarterly dividend amount of 40 cents per share ($1.60 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $234,113 or around 3,750 shares. For a more modest $100 per month or $1,200 per year, you would need $46,823 or around 750 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.60 in this case). So, $6,000 / $1.60 = 3,750 ($500 per month), and $1,200 / $1.60 = 750 shares ($100 per month).
Note that dividend yield can change on a rolling basis as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
CSCO Price Action: Shares of Cisco fell 0.6% to close at $62.43 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

CSCO

How To Earn $500 A Month From Cisco Stock Ahead Of Q2 Earnings

WIIM

ANRO

Alto Neuroscience shares are trading higher after the company announced interim analysis results from its Phase 2b trial of ALTO-300.

Macro Economic Events

Commodities

Economics

OPEC Keeps 2025 Global Economic-Growth Forecast At 3.1%, 2026 Global Economic Growth Forecast At 3.2%; Keeps 2026 Global Oil-Demand Growth At 1.43M B/D And Says US Trade Policy Has Added Uncertainty Into Markets

Nxu shares are trading higher after the company announced shareholder approval of its merger with Verde Bioresins.

ICICI Bank's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBN#NYSE">IBN</a>) short percent of float has fallen 9.8% since its last report. The company recently reported that it has 22.43 million shares sold short, which is 1.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ICICI Bank Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739366125_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ICICI Bank has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing ICICI Bank's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ICICI Bank's peer group average for short interest as a percentage of float is 1.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(IBN) - Analyzing ICICI Bank's Short Interest

Archer Aviation's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) short percent of float has fallen 18.53% since its last report. The company recently reported that it has 47.05 million shares sold short, which is 10.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Archer Aviation Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739366120_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Archer Aviation has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Archer Aviation's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Archer Aviation's peer group average for short interest as a percentage of float is 8.19%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Archer Aviation's Recent Short Interest

UGI's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>) short percent of float has risen 8.43% since its last report. The company recently reported that it has 11.55 million shares sold short, which is 7.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UGI Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739366114_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UGI has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing UGI's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UGI's peer group average for short interest as a percentage of float is 3.02%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(UGI) - Analyzing UGI's Short Interest

WINT

Windtree Therapeutics shares are trading higher after the company announced it gave a presentation for its Phase 2b seismic study of istaroxime at the Technology and Heart Failure Therapeutics Conference in Boston.

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) may have just found its secret weapon to reclaim lost <a href="https://www.benzinga.com/topic/china">ground in China</a> &#8211; Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>). 
After months of uncertainty, Apple has <a href="https://www.reuters.com/technology/apple-partners-with-alibaba-develop-ai-features-iphone-china-information-reports-2025-02-11/">reportedly</a> teamed up with the Chinese tech giant to bring AI features to iPhones in the country, giving investors a reason to cheer.
<h2 class="wp-block-heading">Apple's AI Gamble In China</h2>
The move couldn&#8217;t come at a better time. Huawei has been eating into Apple&#8217;s market share, riding high on AI-powered smartphones, while Apple's latest iPhones have lacked the AI muscle that's become a key selling point. 
With the iPhone 16 getting a boost from China's smartphone subsidies, Apple&#8217;s AI-driven upgrade cycle could be the catalyst needed to reignite sales heading into the iPhone 17 launch.
Read Also: <a href="https://www.benzinga.com/25/02/43631776/apple-teams-up-with-alibaba-for-ai-innovation-in-china-submits-ai-features-for-regulatory-approval">Apple&#8217;s AI Split: Chooses Alibaba For China And OpenAI For Everyone Else</a>
<h2 class="wp-block-heading">JPMorgan Sees A Game-Changer</h2>
JPMorgan analyst Samik Chatterjee sees this as a game-changer. While Apple is keeping quiet for now, reports suggest the company has already submitted its AI models for regulatory approval—positioning itself ahead of the iPhone 17 cycle. 
Chatterjee expects this AI integration to lift investor confidence in Apple's replacement cycle, with the stock's next earnings multiple peak potentially landing in the 32x-33x range.
<h2 class="wp-block-heading">Alibaba Beats Baidu For The AI Spot</h2>
Apple initially eyed Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) for its China AI partner but reportedly wasn't impressed with its progress. Instead, Alibaba won out, thanks in part to its vast user data, which could help Apple train more personalized AI models. 
Given that iPhone sales took a hit last quarter due to missing AI features, this partnership could be Apple's ticket to an AI-powered resurgence in China.
Now, the big question: Will Apple's AI bet be enough to fend off Huawei? 
Investors seem to think so. For now as the stock closed the trading day Tuesday at $232.62, up 2.18%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43647452/apple-follows-trumps-order-renames-gulf-of-mexico-google-already-made-the-change-but-these-two-companies-are-holding-out">Trump White House Boasts Apple&#8217;s &#8216;Gulf Of Mexico&#8217; Rename, But Pinch To Zoom And You Might Be Surprised</a></li>
</ul>

Analyst Color

Asia

Tech

AAPL

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

BIDU

Apple Finds Its AI Wingman In Alibaba - Can It Power An iPhone Comeback In China?

Nxu Announced Shareholder Approval Of Verde Bioresins Merger

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.

AVXL

D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Coincheck Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCK#NASDAQ">CNCK</a>) reported $782.30 million in sales this quarter.

CNCK

Coincheck Group Q3 Sales $782.30M

NKGN

NKGen Biotech shares are trading higher after the company received FDA Fast Track designation for Troculeucel for the treatment of moderate Alzheimer's disease.

MSTU: T-Rex's 2x MicroStrategy ETF Captures Lightning In A Bottle, Turns Into A $3 Billion Behemoth

As risk-taking builds and is rewarded by higher prices, risk-taking morphs into more extreme speculation. For example, the surge of capital into 3x Leveraged S&P 500 ETFs has been remarkable.

Signs Of Extreme Speculation Return

The rising popularity of cryptocurrency and the company synonymous with aggressive Bitcoin (BTC-USD) buying, MicroStrategy ($MSTR), have triggered ...

MicroStrategy (NASDAQ:MSTR) Boom Sparks ETF Chaos

MSTX: Making An Ultra-Bullish Bet On MicroStrategy

MicroStrategy Is A Coiled Spring About To Jump Higher

David Einhorn's Greenlight Capital said in its quarterly letter that it established a new arbitrage position by shorting bitcoin-levered single-sto...

Greenlight owns MicroStrategy as arbitrage play on single-stock ETFs

All The Alpha Is Gone Except For AI - Matthew Tuttle

Greenlight Capital Q4 2024 Letter

MSTU: A Great Fund If You Like Bitcoin To Go Higher

Memecoins: Anyone's Guess As To What Will Happen Next, But It Feels Like It's Going To Be Wild

BITO

BITQ

BITS

BLOK

BWTG

COIN

CPRI

DAPP

ESGX

ETCG

ETHE

FDIG

GBTC

GLRE

GRBK

IBIT

LIVN

LNXSF

LNXSY

MSTR

MSTU

MSTX

MSTZ

NVDX

OBTC

PTON

SATO

SLVYY

SPXL

SVYSF

TSLT

WGMI

Screenshot 2024-10-11 at 5.33.57 PM

ETFs

ETF Opportunities Trust T-Rex 2X Inverse MSTR Daily Target ETF

MSTU And MSTZ: The Only 2x ETFs On MicroStrategy And One Of The Most Volatile Ways To Play Bitcoin

Comments

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF

空売り

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF (BATS:MSTU), 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル